



VETERINARY VACCINES

PRINCIPLES AND APPLICATIONS

FIRST EDITION

EDITED BY

SAMIA METWALLY | GERRIT VILJOEN

AHMED EL IDRISI



Food and Agriculture
Organization of the
United Nations

WILEY Blackwell

Table of Contents

[Cover](#)

[Title Page](#)

[Copyright](#)

[List of Contributors](#)

[Foreword](#)

[Acknowledgments](#)

[Introduction](#)

[Section I: Importance of Veterinary Vaccines](#)

[1 The Role of Veterinary Vaccines in Livestock Production, Animal Health, and Public Health](#)

[1.1 Introduction: The Need for Veterinary Vaccines](#)

[1.2 Diversity of Veterinary Vaccines](#)

[1.3 Vaccines and Food Production](#)

[1.4 Vaccines for Control of Zoonotic Diseases](#)

[1.5 Vaccines to Improve Food Safety](#)

[1.6 Vaccine Banks](#)

[1.7 Successes and Challenges](#)

[1.8 Policies on Use of Vaccines in Disease Control Programs](#)

[1.9 Summary](#)

[Acknowledgments](#)

[References](#)

[2 Principles of Vaccinology and Vaccine Immune Response](#)

[2.1 Introduction](#)

[2.2 The Concept of Immune Conversion](#)

[2.3 Use of Adjuvants](#)

[2.4 Passive Immunity, Induced Immunity, and Individual/Herd Protection](#)

[2.5 Vaccine Delivery Systems](#)

[2.6 Assessing Protection Delivered Through Vaccination - Mode and Level of Protection](#)

[2.7 Benefits of Using DIVA Vaccines](#)

[2.8 Summary](#)

[References](#)

[3 Role of Regional and International Organizations in Vaccine International Standards](#)

[3.1 Introduction](#)

[3.2 The Need for International Vaccine Standardization](#)

[3.3 Key International and Regional Organizations and Their Functions](#)

[3.4 Scope and Role/Functions of Reference and Regional Laboratories](#)

[3.5 Development of Vaccine Standards and Establishment of Rules and Guidelines for Vaccine Standards](#)

[3.6 Accessing Information and Guidance from Reference and Regional Laboratories](#)

[3.7 Summary](#)

[References](#)

[4 Vaccination Strategies, Implementation, and Monitoring](#)

[4.1 Introduction](#)

[4.2 Vaccine-Induced Protection](#)

[4.3 Vaccination Strategies](#)

[4.4 Implementing Vaccination](#)

[4.5 Monitoring and Evaluation of Vaccination](#)

[4.6 Summary](#)

[References](#)

[Section II: Current and Future Veterinary Vaccines](#)

[5 Viral Vaccines](#)

[5.1 Introduction](#)

[5.2 Types of Viral Vaccines](#)

[5.3 Immune Responses to Viral Vaccines](#)

[5.4 Characteristics and Immunity of Each Vaccine Type](#)

[5.5 Vaccine Type Selection](#)

[5.6 Summary](#)

[References](#)

[6 Bacterial and *Mycoplasma* Vaccines](#)

[6.1 Introduction](#)

[6.2 Types of Bacterial Vaccines](#)

[6.3 Bacterial Vaccines as Alternatives to Antibiotics](#)

[6.4 Immune Response to Bacterial Vaccines](#)

[6.5 Vaccination Procedures](#)

[6.6 Vaccines Against Enteric Diseases](#)

[6.7 Bacterial Vaccines Against Abortifacient Diseases](#)

[6.8 Bacterial Vaccines Against Respiratory Diseases](#)

[6.9 *Mycoplasma* Vaccines](#)

[6.10 Other Bacterial Vaccines](#)

[6.11 Summary](#)

[Dedication](#)

[References](#)

[7 Protozoal and Rickettsial Vaccines*](#)

[7.1 Introduction](#)

[7.2 Types of Protozoal and Rickettsial Vaccines](#)

[7.3 Immune Responses to Protozoal and Rickettsial Vaccines](#)

[7.4 Toward Improved Vaccines](#)

[7.5 Summary](#)

[Acknowledgments](#)

[References](#)

[Note](#)

[8 Parasite Vaccines](#)

[8.1 Introduction](#)

[8.2 Types of Vaccines](#)

[8.3 Antigens for Subunit Vaccines](#)

[8.4 Immune Responses to Parasitic Vaccines](#)

[8.5 Summary](#)

[Acknowledgments](#)

[References](#)

[9 Fish Vaccines](#)

[9.1 Introduction](#)

[9.2 Current Fish Vaccines](#)

[9.3 Methods of Administration](#)

[9.4 Nonfish Vaccines](#)

[9.5 Immune Response to Vaccines](#)

[9.6 Future Prospects and Challenges for Fish Vaccines](#)

9.7 Summary

References

10 Novel Developments and Next-Generation Vaccines

10.1 Introduction

10.2 Molecular-Based Technologies in Vaccine Development

10.3 Immune Stimulation Through Antigen Delivery and Molecular Adjuvants

10.4 Plant-Derived Vaccines

10.5 Metabolically Active, Replication Incompetent Vaccines

10.6 Reverse Vaccinology

10.7 Summary

References

Section III: Aspects of Vaccine Production, Quality Control, and Distribution

11 The Manufacture of Veterinary Vaccines: Manufacturing Facilities

11.1 Introduction

11.2 Vaccine Production Systems - General Design and Operating Requirements

11.3 Biosafety Considerations in the Manufacture of Vaccines

11.4 Registration, Licensing, and Authorization of Vaccine Manufacturing Facilities

11.5 Internal and External Audits/Inspections

11.6 Quality Control and Assurance in the Production of Vaccines

11.7 Commercial, Parastatal, and Governmental Vaccine Production Systems

11.8 Summary

References

12 The Manufacture of Veterinary Vaccines: Quality Control of the Manufacturing Process

12.1 Introduction

12.2 General Principles

12.3 Control of Starting and Raw Materials

12.4 Establishment of the Seed Lot Systems for Both Master and Working Seeds

12.5 In-Process Testing

12.6 Internal and External Proficiency Testing

12.7 Summary

References

13 The Manufacture of Veterinary Vaccines: Control of Final Product

13.1 Introduction

13.2 Control Tests on the Finished Product

13.3 Key Aspects and Types of Efficacy/Potency Testing Either In Vivo or In Vitro

13.4 Key Aspects and Types of Safety Testing

13.5 Summary

References

14 Registration of Veterinary Vaccines with Respect to Consistency, Safety, and Efficacy

14.1 Introduction

14.2 Legislative Mechanisms/Systems Including Marketing Authorization Procedures

14.3 Requirements for Registration and Authorization Including Quality, Safety, and Efficacy Assessment

[14.4 Batch-to-Batch Consistency Assessment Through In-Process and Final Product Testing](#)

[14.5 Stability Testing](#)

[14.6 Demonstrating Safety](#)

[14.7 Demonstrating Efficacy to Confirm Claims Made for the Product](#)

[14.8 Special Licensing Considerations](#)

[14.9 Minimum Requirements for Monitoring Systems \(Legislation\)](#)

[14.10 Summary](#)

[References](#)

[15 Aspects of Vaccine Accessibility and Commercialization](#)

[15.1 Introduction](#)

[15.2 Development](#)

[15.3 Commercialization](#)

[15.4 Accessibility](#)

[15.5 Challenges of Producing Vaccine in the Country](#)

[15.6 Antigen or Vaccine Bank Systems](#)

[15.7 Improving Accessibility](#)

[15.8 Summary](#)

[References](#)

[16 Vaccine Strategic Reserves](#)

[16.1 Introduction](#)

[16.2 Types of Strategic Reserves or Banks](#)

[16.3 Requirements for Strategic Reserves or Banks](#)

[16.4 What and How Much Vaccine Should Be Stored in a Strategic Reserve?](#)

[16.5 Selecting and Sourcing Candidate Vaccines for a Reserve](#)

[16.6 Acceptance Testing – Ensuring Safety, Efficacy, and Quality of Strategic Vaccines](#)

[16.7 Storage and Monitoring of Strategic Vaccines](#)

[16.8 Future Developments for Strategic Vaccine Banks](#)

[16.9 Summary](#)

[References](#)

[Section VI: Veterinary Vaccines for Selected Animal Diseases](#)

[17 Foot and Mouth Disease](#)

[17.1 Introduction](#)

[17.2 Types of Vaccines](#)

[17.3 Immune Response and Duration of Immunity](#)

[17.4 Vaccine Selection](#)

[17.5 Desired Specifications When Ordering Vaccine](#)

[17.6 Quality Assurance and Control Testing](#)

[17.7 Vaccine Application for Disease Control](#)

[17.8 Combination with Other Vaccines](#)

[17.9 Postvaccination Monitoring](#)

[17.10 Outbreaks in Vaccinated Animals](#)

[17.11 Vaccine Adverse Reactions](#)

[17.12 List of Manufacturers](#)

[17.13 Summary](#)

[References](#)

[18 Avian Influenza](#)

[18.1 Introduction](#)

[18.2 Types of Vaccines](#)

[18.3 Immune Response and Duration of Immunity](#)

[18.4 Desired Specifications when Ordering Vaccine](#)

[18.5 Quality Assurance and Control Testing](#)

[18.6 Vaccine Application for Disease Control](#)

[18.7 Monitoring and Vaccine Effectiveness](#)

[18.8 Vaccine Adverse Reactions](#)

[18.9 Availability and List of Manufacturers](#)

[18.10 Future Considerations](#)

[18.11 Summary](#)

[References](#)

[Note](#)

[19 Rift Valley Fever](#)

[19.1 Introduction](#)

[19.2 Properties of RVFV Proteins and Rationale for the Design of Safe Vaccines](#)

[19.3 Licensed Veterinary Vaccines](#)

[19.4 Vaccination Strategies and Guidelines](#)

[19.5 Next-Generation Vaccines](#)

[19.6 Desired Specifications and Requirements of RVF Vaccines](#)

[19.7 Summary](#)

[References](#)

[Note](#)

[20 Bluetongue](#)

[20.1 Introduction](#)

[20.2 History and Epidemiology](#)

[20.3 Costs and Trade Implications](#)

[20.4 Vaccines](#)

[20.5 BT Vaccines in the Pipeline](#)

[20.6 Immune Response and Duration of Immunity](#)

[20.7 Vaccination Strategies](#)

[20.8 Summary](#)

[References](#)

[21 Peste des Petits Ruminants](#)

[21.1 Introduction](#)

[21.2 Types of Vaccines Commercially Available](#)

[21.3 Immune Response and Duration of Immunity](#)

[21.4 Desired Specifications When Ordering Vaccine](#)

[21.5 Quality Assurance and Control Testing](#)

[21.6 Vaccine Application for Disease Control](#)

[21.7 Monitoring and Evaluation of Vaccination Campaigns and Their Effectiveness](#)

[21.8 Availability and List of Manufacturers](#)

[21.9 Summary and Conclusions](#)

[References](#)

[22 Brucellosis](#)

[22.1 Introduction](#)

[22.2 The Requirements of Brucellosis Vaccines](#)

[22.3 Brucellosis Live Vaccines](#)

[22.4 Strategies for Controlling Ruminant Brucellosis](#)

[22.5 Conclusions](#)

[22.6 Summary](#)

[Acknowledgments](#)

[References](#)

[Notes](#)

[23 Contagious Bovine Pleuropneumonia](#)

[23.1 Introduction](#)

[23.2 Types of Vaccines](#)

[23.3 Immune Response and Duration of Immunity](#)

[23.4 Desired Specifications When Ordering Vaccine](#)

[23.5 Quality Assurance and Control Testing](#)

[23.6 Vaccine Application for Disease Control](#)

[23.7 Monitoring and Vaccine Effectiveness \(with the T1/44 Vaccines\)](#)

[23.8 Vaccine Adverse Reactions](#)

[23.9 Availability and List of Manufacturers](#)

[23.10 Summary](#)

[References](#)

[24 Classic Swine Fever](#)

[24.1 Introduction](#)

[24.2 Types of Vaccines](#)

[24.3 Immune Response and Duration of Immunity](#)

[24.4 Desired Specifications When Ordering Vaccine](#)

[24.5 Quality Assurance and Control Testing](#)

[24.6 Vaccine Application for Disease Control](#)

[24.7 Monitoring and Vaccine Effectiveness](#)

[24.8 Adverse Reactions to Vaccination](#)

[24.9 Availability and List of Manufacturers](#)

[24.10 Summary](#)

[References](#)

[25 Newcastle Disease](#)

[25.1 Introduction](#)

[25.2 Types of Vaccines](#)

[25.3 Immune Response and Duration of Immunity](#)

[25.4 Desired Specifications when Ordering Vaccine](#)

[25.5 Quality Assurance and Control Testing](#)

[25.6 Vaccine Application for Disease Control](#)

[25.7 Monitoring and Vaccine Effectiveness](#)

[25.8 Vaccine Adverse Reactions](#)

[25.9 Availability and List of Manufacturers](#)

[25.10 Summary](#)

[References](#)

[26 Porcine Reproductive and Respiratory Syndrome](#)

[26.1 Introduction](#)

[26.2 Types of Vaccines](#)

[26.3 Immune Response and Duration of Immunity](#)

[26.4 Desired Specifications When Ordering a Vaccine](#)

[26.5 Quality Assurance and Control Testing](#)

[26.6 Vaccine Application for Disease Control](#)

[26.7 Consideration of Epidemiological Factors and Control Objectives](#)

[26.8 Combination Vaccines for PRRSV and Other Diseases](#)

[26.9 Use of Vaccine in the Face of an Outbreak](#)

[26.10 Monitoring and Vaccine Effectiveness](#)

[26.11 Vaccine Adverse Reactions](#)

[26.12 Summary](#)

[Acknowledgments](#)

[References](#)

[27 Anthrax](#)

[27.1 Introduction](#)

[27.2 Types of Vaccines](#)

[27.3 Immune Response and Duration of Immunity](#)

[27.4 Desired Specifications when Ordering Vaccine](#)

[27.5 Quality Assurance and Control](#)

[27.6 Vaccine Application for Disease Control](#)

[27.7 Management of Anthrax Outbreaks](#)

[27.8 Anthrax Vaccines for Wildlife](#)

[27.9 Monitoring and Vaccine Effectiveness](#)

[27.10 Vaccine Adverse Reactions](#)

[27.11 Availability and List of Manufacturers](#)

[27.12 Summary](#)

[References](#)

[28 Capripox \(Lumpy Skin Disease, Sheep Pox, and Goat Pox\)](#)

[28.1 Introduction](#)

[28.2 Types of Vaccines](#)

[28.3 Immune Response and Duration of Immunity](#)

[28.4 Vaccine Quality Assurance and Control Testing](#)

[28.5 Vaccine Application for Disease Control](#)

[28.6 Vaccines Against CaPV and Other Diseases](#)

[28.7 Vaccine Effectiveness and Postvaccination Monitoring](#)

[28.8 Vaccine Adverse Reactions](#)

[28.9 Availability and a List of Manufacturers](#)

[28.10 Summary](#)

[References](#)

[29 Rabies](#)

[29.1 Introduction](#)

[29.2 Types of Vaccines](#)

[29.3 Immune Response](#)

[29.4 Presentation, Indications, and Dosage](#)

[29.5 Regulations and Quality Assurance](#)

[29.6 Vaccine Application for Disease Prevention in Livestock and Other Animals](#)

[29.7 Monitoring and Vaccine Effectiveness](#)

[29.8 Availability](#)

[29.9 Summary](#)

[References](#)

[Index](#)

[End User License Agreement](#)

List of Tables

Chapter 2

[Table 2.1 Most commonly used adjuvants, their mode of action, and advantages ...](#)

[Table 2.2 Vaccine delivery systems.](#)

[Table 2.3 Main gaps in our knowledge.](#)

Chapter 4

[Table 4.1 Some of the many steps and procedures to be established and reviewed...](#)

Chapter 5

[Table 5.1 Examples of nonconventional new-generation veterinary vaccines.](#)

Chapter 6

[Table 6.1 Characteristics of most common veterinary bacterial vaccines.](#)

Chapter 7

[Table 7.1 Vaccine candidates against salivarian trypanosome infections histor...](#)

[Table 7.2 Specificity of available live attenuated vaccines against tropical ...](#)

[Table 7.3 Vaccines available against bovine babesiosis.](#)

[Table 7.4 Vaccination strategies tested for bovine anaplasmosis \(Kocan et al....](#)

[Table 7.5 Vaccination strategies tested for heartwater.](#)

Chapter 8

[Table 8.1 Recombinant vaccine antigens which confer partial protection against...](#)

Chapter 9

[Table 9.1 Advantages and disadvantages of different methods of fish vaccine d...](#)

Chapter 16

[Table 16.1 Procedures followed by the International Vaccine Bank in order to ...](#)

[Table 16.2 Key elements in the establishment and management of vaccine banks.](#)

Chapter 17

[Table 17.1 List of FMD vaccine manufacturers.](#)

Chapter 18

[Table 18.1 Properties of an ideal avian influenza vaccine for poultry.](#)

[Table 18.2 Current vaccine technologies licensed and used in the field for H5...](#)

[Table 18.3 Experimental AIV vaccines using technologies that are not currentl...](#)

[Table 18.4 Data on the 113 billion doses of H5/H7 AIV vaccine used in poultry...](#)

[Table 18.5 Data on the 10.1 billion doses of H5/H7 AIV vaccine used in poultr...](#)

Chapter 19

[Table 19.1 List of the principal RVF epizootics.](#)

[Table 19.2 RVF vaccines manufactured in Africa.](#)

Chapter 20

[Table 20.1 Vaccines by country of registration \(at time of publication\).](#)

Chapter 21

[Table 21.1 Live attenuated PPRV vaccine strains commercially available \(2018\)...](#)

[Table 21.2 List of PPR vaccine manufacturers \(2018\).](#)

Chapter 22

[Table 22.1 General characteristics of currently available brucellosis vaccine...](#)

[Table 22.2 Protein-deleted *Brucella* mutants that have been tested in natural h...](#)

Chapter 23

[Table 23.1 CBPP vaccines: advantages and drawbacks.](#)

Chapter 24

[Table 24.1 Vaccination decision criteria.](#)

Chapter 25

[Table 25.1 Vaccination strategies for different epidemiological scenarios.](#)

[Table 25.2 List of Newcastle disease vaccine manufacturers.](#)

Chapter 26

[Table 26.1 List of manufacturers of vaccines for PRRS.](#)

[Table 26.2 Categorization of PRRSV infection status in swine herds.a](#)

Chapter 28

[Table 28.1 List of lumpy skin disease \(LSD\), sheep pox \(SPP\), and goat pox \(G...](#)

List of Illustrations

Chapter 1

[Figure 1.1 Global population growth in recent centuries, projected through 2...](#)

[Figure 1.2 Global production of meat and eggs. Between 1962 and 2006 the pro...](#)

[Figure 1.3 Emerging diseases affecting various animal species.](#)

Chapter 2

[Figure 2.1 Effector functions of antibodies and T cells. \(a\) Effector functi...](#)

Chapter 3

[Figure 3.1 Key international and regional organizations.](#)

[Figure 3.2 OIE standard setting process.](#)

Chapter 4

[Figure 4.1 Determinants of vaccination program effectiveness for the control...](#)

Chapter 7

[Figure 7.1 \(a\) Vector, \(b\) infected host cell morphology, and \(c\) life cycle...](#)

[Figure 7.2 \(a\) Vector, \(b\) infected host cell morphology, and \(c\) life cycle...](#)

[Figure 7.3 \(a\) Vector, \(b\) infected host cell morphology, and \(c\) life cycle...](#)

[Figure 7.4 \(a\) Vector, \(b\) infected host cell morphology, and \(c\) life cycle...](#)

[Figure 7.5 \(a\) Vector, \(b\) infected host cell morphology, and \(c\) life cycle...](#)

[Figure 7.6 \(a\) Vector, \(b\) infected host cell morphology, and \(c\) life cycle...](#)

Chapter 8

[Figure 8.1. Design of vaccines - from antigens to a product.](#)

Chapter 9

[Figure 9.1 Vaccination of sedated fish is performed by hand, normally by an ...](#)

[Figure 9.2 Fish are held ventral side up for vaccination and the needle is i...](#)

Chapter 10

[Figure 10.1 Multiple pathways of vaccine development. Rational design of vac...](#)

Chapter 12

[Figure 12.1 \(a\) Overview of quality controls required for the production of ...](#)

Chapter 15

[Figure 15.1 Veterinary vaccines market, 2015, by revenue.](#)

[Figure 15.2 Stages in vaccine development.](#)

[Figure 15.3 Impact of plant utilization on cost of goods.](#)

[Figure 15.4 Impact of vial size on cost per dose.](#)

[Figure 15.5 Possible distribution route for vaccine.](#)

[Figure 15.6 Possible steps to accessibility.](#)

Chapter 17

[Figure 17.1 Global map with distribution of FMD serotypes among the seven vi...](#)

[Figure 17.2 Schematic representation of reactive vaccination and associated ...](#)

[Figure 17.3 Reproduction number. \(a\) The basic reproduction number \(\$R_0\$ \) is t...](#)

[Figure 17.4 Relationship between the basic reproduction number \(\$R_0\$ \) and the ...](#)

[Figure 17.5 Factors contributing to vaccine and vaccination failures.](#)

Chapter 18

[Figure 18.1 Schematic of technologies used for the five registered types of ...](#)

Chapter 19

[Figure 19.1 Schematic representation of the L, M, and S segments of the RVFV...](#)

[Figure 19.2 \(a\) Vero cells infected with a virulent strain of RVFV \(ZH5\). St...](#)

Chapter 21

[Figure 21.1 Peste des petits ruminants events from January 2007 to 31 Decemb...](#)

[Figure 21.2 Phylogenetic tree of partial N gene sequences from different PPR...](#)

Chapter 22

[Figure 22.1 Impact of three different eradication strategies on mean herd pr...](#)

[Figure 22.2 Conjunctival vaccination. \(a\) For animals that are not handled f...](#)

[Figure 22.3 Evolution of ovine and caprine brucellosis in Spain. The plots r...](#)

Chapter 23

[Figure 23.1 The map shows the estimated distribution of CBPP and how it has ...](#)

[Figure 23.2 “Willems reaction” following inoculation of T1/44 vaccine. T1/44...](#)

Chapter 29

[Figure 29.2 A representative lyssavirus virion with a typical bullet-shaped ...](#)

[Figure 29.1 Generalized depiction of intraspecific transmission pathways of ...](#)

Veterinary Vaccines: Principles and Applications

Published by

The Food and Agriculture Organization of the United Nations

and

John Wiley & Sons Limited

Edited by

Samia Metwally

Senior Animal Health Officer

Animal Production and Health Division

Food and Agriculture Organization of the United Nations

Gerrit Viljoen

Section Head, Animal Production and Health

Joint FAO/IAEA Center

International Atomic Energy Agency

Ahmed El Idrissi

Former, Senior Animal Health Officer

Animal Production and Health Division

Food and Agriculture Organization of the United Nations

This edition first published 2021

© 2021 FAO

The Food and Agriculture Organization (FAO) is a specialized agency of the United Nations that leads international efforts to defeat hunger. Our goal is to achieve food security for all and make sure that people have regular access to enough high-quality food to lead active, healthy lives. With over 194 member states, FAO works in over 130 countries worldwide. We believe that everyone can play a part in ending hunger.

All rights reserved. Reproduction and dissemination of material in this information product for educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Reproduction of material in this information product for resale or other commercial purposes is prohibited without written permission of the copyright holder. Applications for such permission should be addressed to the Chief, Publications Branch, Office of Communications, FAO, Viale delle Terme di Caracalla, 00153 Rome, Italy or by e-mail to copyright@fao.org.

The right of Samia Metwally, Gerrit Viljoen and Ahmed El Idrissi to be identified as the authors of the editorial material in this work has been asserted in accordance with law.

Registered Office

John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

Editorial Office

9600 Garsington Road, Oxford, OX4 2DQ, UK

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Limit of Liability/Disclaimer of Warranty

The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Food and Agriculture Organization of the United Nations concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or products of manufacturers, whether or not these have been patented, does not imply that these have been endorsed or recommended by the Food and Agriculture Organization of the United Nations in preference to others of a similar nature that are not mentioned. The views expressed herein are those of the authors and do not necessarily represent those of the Food and Agriculture

Organization of the United Nations. The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting vaccine development or application for animal diseases. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is published with the understanding that the publisher or FAO is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher, FAO nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data

Names: Metwally, Samia, editor. | Viljoen, Gerrit J., editor. | El Idrissi, Ahmed, editor.

Title: Veterinary vaccines : principles and applications / edited by Samia Metwally, Gerrit Viljoen, Ahmed El Idrissi.

Other titles: Veterinary vaccines (Metwally)

Description: Hoboken, NJ : Wiley-Blackwell, 2020. | Includes bibliographical references and index. | Description based on print version record and CIP data provided by publisher; resource not viewed.

Identifiers: LCCN 2020029897 (print) | LCCN 2020029898 (ebook) | ISBN9781119506270 (epub) | ISBN 9781119506263 (adobe pdf) | ISBN 9781119505952(hardback) | ISBN 9781119505952q(hardback) | ISBN 9781119506263q(adobepdf) | ISBN 9781119506270q(epub)

Subjects: | MESH: Vaccines | Vaccination-veterinary | Livestock | Poultry | Animal Diseases-prevention & control

Classification: LCC SF

918.V32 (ebook) | LCC SF918.V32 (print) | NLM SF918.V32 | DDC 636.089/5372-dc23

LC record available at <https://lccn.loc.gov/2020029897>

LC record available at <https://lccn.loc.gov/2020029898>

Cover Design: Wiley

Cover Images: United States Department of Agriculture, public domain

List of Contributors

Alexandra Adams BSc, PhD

Professor of Aquatic Immunology and Diagnostics
Institute of Aquaculture, School of Natural Sciences
University of Stirling
Stirling, Scotland, UK

William Amanfu DCM, MS

International Veterinary Consultant
Formerly Animal Health Officer
FAO/UN
Rome, Italy

John Atkinson BSc Hons

Technical Manager, Ruminants
MSD Animal Health
Milton Keynes
Buckinghamshire, UK

Paul Barnett CBiol MRSB PhD

Biologicals Assessor
Veterinary Medicines Directorate
Addlestone, Surrey, UK

Carrie Batten Dr PhD

Head of Vascular Research Laboratory

The Pirbright Institute
Woking, Surrey, UK

Imane Belkourati DVM

Head of Quality Assurance
MCI Santé Animale
Mohammedia, Morocco

Abdelali Benkirane DVM, PhD

Full Professor
Microbiology, Immunology and Contagious Diseases
Unit, Department of Pathology and Veterinary Public
Health
Institut Agronomique et Vétérinaire Hassan II
Rabat, Morocco

José Maria Blasco PhD

Ad Honorem Researcher
Animal Health Department IA2 CITA
Universidad de Zaragoza
Zaragoza, Spain

Michèle Bouloy

Head of Research Unit “Molecular Genetics of
Bunyavirus”
Department of Virology
Institut Pasteur
Paris, France

Zineb Boumart PhD

Research and Development Coordinator
MCI Santé Animale
Mohammedia, Morocco

Ian Brown MIBiol PhD

Head of Virology Department
Director of OIE/FAO International Reference
Laboratory for Avian Influenza and Newcastle Disease
Animal and Plant Health Agency
Addlestone, Surrey, UK

Emanuele Campese MSc

Researcher
Italian Reference Centre for Anthrax
Istituto Zooprofilattico Sperimentale della Puglia e
della Basilicata
Foggia, Italy

Peter Cargill BVM, CertPMP, MRCVS

Director
Wyatt Poultry Veterinary Services
Hereford, UK

Bryan Charleston BVM, MSc, PhD, MRCVS

Director
The Pirbright Institute
Pirbright, Surrey, UK

Adela Chavez PhD

Postdoctoral Researcher
CIRAD, UMR ASTRE
Petit-Bourg
Guadeloupe, French West Indies
CIRAD INRA, ASTRE
University of Montpellier
Montpellier, France

Karin Darpel VetMed, MRCVS, PhD

Head of Orbivirus Research
The Pirbright Institute
Woking, Surrey, UK

Klaus Depner DVM

Senior Scientific Officer
FAO Reference Centre for Classical Swine Fever
Friedrich-Loeffler-Institut
Greifswald, Germany

Adama Diallo DVM, PhD

Adviser to the Director
ISRA/LNERV
Dakar Hann, Senegal
UMR CIRAD-INRA ASTRE
Montpellier
France

Klaas Dietze DVM

Senior Scientific Officer
FAO Reference Centre for Classical Swine Fever
Friedrich-Loeffler-Institut
Greifswald, Germany

Meritxell Donadeu DVM, MSc

Visiting Research Fellow
Faculty of Veterinary and Agricultural Sciences
Veterinary Clinical Centre
The University of Melbourne
Werribee, Australia

Adelia Donatiello MSc

Researcher
Italian Reference Centre for Anthrax
Istituto Zooprofilattico Sperimentale della Puglia e
della Basilicata
Foggia, Italy

Baptiste Dungu DVM, PhD

CEO
Onderstepoort Biological Products SOC Ltd
Onderstepoort, South Africa

Mehdi El Harrak DVM, PhD

R&D Director
MCI Santé Animale
Mohammedia, Morocco